Page 12 Volume 20 - N2 - 2012

A. Charrua, et al.: TRPV1 e Dor Visceral
86. Sanchez JF, Krause JE, Cortright DN. The distribution and regulation 111. Giannantoni A, Di Stasi SM, Stephen RL, et al. Intravesical capsaicin
of vanilloid receptor VR1 and VR1 5’ splice variant RNA expression versus resiniferatoxin in patients with detrusor hyperreflexia: a pro-
in rat. Neuroscience. 2001;107:373-81. spective randomized study. J Urol. 2002;167:1710-4.
87. Lu G, Henderson D, Liu L, Reinhart PH, Simon SA. TRPV1b, a func- 112. Igawa Y, Satoh T, Mizusawa H, et al. The role of capsaicin-sensitive
tional human vanilloid receptor splice variant. Molecular Pharmacol. afferents in autonomic dysreflexia in patients with spinal cord injury.
2005;67:1119-27. BJU Int. 2003;91:637-41.
88. Morenilla-Palao C, Planells-Cases R, García-Sanz N, Ferrer-Montiel 113. Kim JH, Rivas DA, Shenot PJ, et al. Intravesical resiniferatoxin for
A. Regulated exocytosis contributes to protein kinase C potentiation refractory detrusor hyperreflexia: a multicenter, blinded, randomized,
of vanilloid receptor activity. J Biol Chem. 2004;279:25665-72. placebo-controlled trial. J Spinal Cord Med. 2003;26:358-63.
89. Bhave G, Zhu W, Wang H, Brasier DJ, Oxford GS, Gereau RW 4th. 114. Novakova-Tousova K, Vyklicky L, Susankova K, et al. Functional © Permanyer Portugal 2012
cAMP-dependent protein kinase regulates desensitization of the capsai- changes in the vanilloids receptor subtype 1 channel during and
cin receptor (VR1) by direct phosphorylation. Neuron. 2002;35:721-31. after acute desensitization. Neuroscience. 2007;149:144-54.
90. Van Buren JJ, Bhat S, Rotello R, Pauza ME, Premkumar LS. Sensi- 115. Vyklicky L, Nováková-Tousová K, Benedikt J, Samad A, Touska F,
tization and translocation of TRPV1 by insulin and IGF-I. Molecular Vlachová V. Calcium-dependent desensitization of vanilloid receptor
Pain. 2005;1:17-28. TRPV1: a mechanism possibly involved in analgesia induced by
91. Fowler CJ, Jewkes D, McDonald WI, Lynn B, de Groat WC. Intra- topical application of capsaicin. Physiol Res. 2008;57:S59-68.
vesical capsaicin for neurogenic bladder dysfunction. Lancet. 116. Lee SY, Lee JH, Kang KK, Hwang SY, Choi KD, Oh U. Sensitization
1992;339:1239. of vanilloid receptor involves an increase in the phosphorylated form
92. Fowler CJ, Beck RO, Gerrard S, Betts CD, Fowler CG. Intravesical of the channel. Arch Pharm Res. 2005;28:405-12.
capsaicin for treatment of detrusor hyperreflexia. J Neurol Neurosurg 117. Piper AS, Yeats JC, Bevan S, Docherty RJ. A study of the voltage
Psychiatry. 1994;57:169-73. dependence of capsaicin-activated membrane currents in rat sen-
93. Geirsson G, Fall M, Sullivan L. Clinical and urodynamic effects of sory neurones before and after acute desensitization. J Physiol.
intravesical capsaicin treatment in patients with chronic traumatic 1999;518:721-33.
spinal detrusor hyperreflexia. J Urol. 1995;154:1825-9. 118. Koplas PA, Rosenberg RL, Oxford GS. The role of calcium in the
94. Chandiramani VA, Peterson T, Duthie GS, Fowler CJ. Urodynamic desensitization of capsaicin responses in rat dorsal root ganglion
changes during therapeutic intravesical instillations of capsaicin. Br neurons. J. Neurosci. 1997;17:3525-37.
J Urol. 1996;77:792-7. 119. Mohapatra DP, Nau C. Regulation of Ca2+-dependent desensitiza-
95. Das A, Chancellor MB, Watanabe T, Sedor J, Rivas DA. Intravesical tion in the vanilloids receptor TRPV1 by calcineurin and cAMP-de-
capsaicin in neurologic impaired patients with detrusor hyperre- pendent protein kinase. J Biol Chem. 2005;280:13424-32.
flexia. J Spinal Cord Med. 1996;19:190-3. 120. Docherty RJ, Yeats JC, Bevan S, Boddeke HW. Inhibition of calcineu-
96. Lazzeri M, Beneforti P, Benaim G, Maggi CA, Lecci A, Turini D. In- rin inhibits the desensitization of capsaicin-evoked currents in cul-
travesical capsaicin for treatment of severe bladder pain: a random- tured dorsal root ganglion neurones from adult rats. Pflugers Arch.
ized placebo controlled study. J Urol. 1996;156:947-52. 1996;431:828-37.
97. Lazzeri M, Beneforti P, Turini D. Urodynamic effects of intravesical 121. Lazzeri M, Beneforti P, Spinelli M, Zanollo A, Barbagli G, Turini D.
resiniferatoxin in humans: preliminary results in stable and unstable Intravesical resiniferatoxin for the treatment of hypersensitive disor-
detrusor. J Urol. 1997;158:2093-6. der: a randomized placebo controlled study. J Urol. 2000;164:676-9.
98. Lazzeri M, Spinelli M, Beneforti P, Zanollo A, Turini D. Intravesical 122. Cruz F. Vanilloid receptor and detrusor instability. Urology. 2002;59:51-60.
resiniferatoxin for the treatment of detrusor hyperreflexia refractory 123. Payne CK, Mosbaugh PG, Forrest JB, et al.; ICOS RTX Study Group
to capsaicin in patients with chronic spinal cord diseases. Scand J (Resiniferatoxin Treatment for Interstitial Cystitis). Intravesical res-
Urol Nephrol. 1998;32:331-4. iniferatoxin for the treatment of interstitial cystitis: a randomized,
99. Lazzeri M, Spinelli M, Zanollo A, Turini D. Intravesical vanilloids and double-blind, placebo controlled trial. J Urol. 2005;173:1590-4.
neurogenic incontinence: ten years experience. Urol Int. 2004; 124. Chen TY, Corcos J, Camel M, Ponsot Y, Tu le M. Prospective, ran-
72:145-9. domized, double-blind study of safety and tolerability of intravesical
100. Cruz F, Guimarães M, Silva C, Rio ME, Coimbra A, Reis M. Desen- resiniferatoxin (RTX) in interstitial cystitis (IC). Int Urogynecol J Pelvic
sitization of bladder sensory fibres by intravesical capsaicin has long Floor Dysfunct. 2005;16:293-7.
lasting clinical and urodynamic effects in patients with hyperactive 125. Brady CM, Apostolidis A, Yiangou Y, et al. P2X3-immunoreactive
or hypersensitive bladder dysfunction. J Urol. 1997;157:585-9. nerve fibres in neurogenic detrusor overactivity and the effect of
101. Cruz F, Guimaräes M, Silva C, Reis M. Suppression of bladder hyper- intravesical resiniferatoxin. Eur Urol. 2004;46:247-53.
reflexia by intravesical resiniferatoxin. Lancet. 1997;350:640-1. 126. Gunthorpe MJ, Chizh BA. Clinical development of TRPV1 antago-
102. De Ridder D, Chandiramani V, Dasgupta P, Van Poppel H, Baert L, nists: targeting a pivotal point in the pain pathway. Drug Discov
Fowler CJ. Intravesical capsaicin as a treatment for refractory detru- Today. 2009;14:56-67.
sor hyperreflexia: a dual center study with long-term followup. J Urol. 127. Khairatkar-Joshi N, Szallasi A. TRPV1 antagonists: the challenges Sem o consentimento prévio por escrito do editor, não se pode reproduzir nem fotocopiar nenhuma parte desta publicação.
1997;158:2087-92. for therapeutic targeting. Trends Mol Med. 2009;15:14-22.
103. de Séze M, Wiart L, Joseph PA, Dosque JP, Mazaux JM, Barat M. 128. Charrua A, Cruz CD, Narayanan S, et al. GRC-6211, a new oral spe-
Capsaicin and neurogenic detrusor hyperreflexia. A double blind cific TRPV1 antagonist, decreases bladder overactivity and noxious
placebo controlled study in 20 patients with spinal cord lesions. bladder input in cystitis animal models. J Urol. 2009;181:379-86.
Neurourol Urodyn. 1998;17:513-23. 129. Andersson KE. New pharmacologic targets for the treatment of the
104. de Sèze M, Wiart L, Ferrière J, de Sèze MP, Joseph P, Barat M. overactive bladder: an update. Urology. 2004;63:32-41.
Intravesical instillation of capsaicin in urology: A review of the litera- 130. Theoharides TC. Treatment approaches for painful bladder syn-
ture. Eur Urol. 1999;36:267-77. drome/interstitial cystitis. Drugs. 2007;67:215-35.
105. de Sèze M, Wiart L, de Sèze MP, et al. Intravesical capsaicin versus 131. Mourtzoukou EG, Iavazzo C, Falagas ME. Resiniferatoxin in the
resiniferatoxin for the treatment of detrusor hyperreflexia in spinal treatment of interstitial cystitis: a systematic review. Int Urogynecol
cord injured patients: a double-blind, randomized, controlled study. J Pelvic Floor Dysfunct. 2008;19:1571-6.
J Urol. 2004;171:251-5. 132. Steiner AA, Turek VF, Almeida MC, et al. Nonthermal activation of
106. de Sèze M, Gallien P, Denys P, et al. Intravesical glucidic capsaicin transient receptor potential vanilloid-1 channels in abdominal viscera
versus glucidic solvent in neurogenic detrusor overactivity: a double tonically inhibits autonomic cold-defense effectors. J Neurosc.
blind controlled randomized study. Neurourol Urodyn. 2006;25:752-7. 2007;27:7459-68.
107. Wiart L, Joseph PA, Petit H, et al. The effects of capsaicin on the 133. Swanson DM, Dubin AE, Shah C, et al. Identification and biological
neurogenic hyperreflexic detrusor. A double blind placebo controlled evaluation of 4-(3-trifluoromethylpyridin-2-yl)piperazine-1-carboxylic
study in patients with spinal cord disease. Preliminary results. Spinal acid (5-trifluoromethylpyridin-2-yl)amide, a high affinity TRPV1 (VR1)
Cord. 1998;36:95-9. vanilloid receptor antagonist. J Med Chem. 2005;48:1857-72.
108. Chancellor MB, de Groat WC. Intravesical capsaicin and resinifera- 134. Gavva NR, Bannon AW, Surapaneni S, et al. The vanilloid receptor
toxin therapy: spicing up the ways to treat the overactive bladder. J TRPV1 is tonically activated in vivo and involved in body temperature
Urol. 1999;162:3-11. regulation. J Neurosci. 2007;27:3366-3374.
109. Fagerli J, Fraser MO, deGroat WC, et al. Intravesical capsaicin for 135. Gavva NR, Treanor JJ, Garami A, et al. Pharmacological blockade
the treatment of interstitial cystitis: a pilot study. Can J Urol. of the vanilloid receptor TRPV1 elicits marked hyperthermia in hu-
1999;6:737-44. mans. Pain. 2008;136:202-10.
110. Silva C, Rio ME, Cruz F. Desensitization of bladder sensory fibers 136. Wong GY, Gavva NR. Therapeutic potential of vanilloid receptor
by intravesical resiniferatoxin, a capsaicin analog: long-term results TRPV1 agonists and antagonists as analgesics: Recent advances
for the treatment of detrusor hyperreflexia. Eur Urol. 2000;38:444-52. and setbacks. Brain Res Rev. 2008;60:267-77.

DOR

11